Battle report
CJC-1295 vs Ipamorelin
Two GH-axis research peptides compared by mechanism, evidence, risk, and anti-doping status.
CJC-1295 and ipamorelin are often discussed together, but comparing biomarker effects is not the same as proving body-composition, recovery, or longevity outcomes.
CJC-1295
Ipamorelin
Concise answer
Which wins: CJC-1295 vs Ipamorelin?
CJC-1295 and ipamorelin are often discussed together, but comparing biomarker effects is not the same as proving body-composition, recovery, or longevity outcomes.
Battle table
Head-to-Head Comparison
| Factor | CJC-1295 | Ipamorelin | Edge |
|---|---|---|---|
| Mechanism lane | GHRH analog | Ghrelin/GH secretagogue pathway | Different |
| Human data | Small biomarker studies | Human PK/PD studies | Split |
| Outcome proof | Weak for wellness outcomes | Weak for wellness outcomes | Neither |
| Anti-doping risk | High | High | Tie |
Winner map
Evidence, Safety, Legality
- Evidence: CJC-1295 for published GH/IGF-1 biomarker work; ipamorelin for selective secretagogue pharmacology
- Safety: No broad winner
- Legal: Neither for casual consumer use
Plain English
Takeaways
- The popular stack is much more famous than its clinical outcome evidence.
- GH and IGF-1 changes are biomarkers, not proof of better health.
- Hormone-axis questions should be handled with medical testing and supervision.
Internal links
Read the Profiles
Common Questions
Are CJC-1295 and ipamorelin commonly combined?
They are commonly discussed together online, but PeptideWars does not provide stacking or dosing guidance.
Which has better evidence?
Both have limited human evidence focused on pharmacology and biomarkers rather than broad clinical outcomes.
Are they banned in sport?
Growth hormone releasing factors and secretagogues are high-risk under anti-doping rules. Check WADA and sport-specific guidance.